CrystalGenomics

Seongnam-si, South Korea Founded: 2000 • Age: 26 yrs
Clinical stage pharmacy company focused on the novel drugs in areas of inflammation, oncology, and infectious disease
Annual revenue $4.9M Latest available
Total funding - 3 rounds
Employees 80 Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About CrystalGenomics

CrystalGenomics is a company based in Seongnam-si (South Korea) founded in 2000. The company has 80 employees as of December 31, 2024.

  • Headquarter Seongnam-si, South Korea
  • Employees 80 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cg Invites Co., Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $4.92 M (USD)
    48.67
    as on Dec 31, 2024
  • Net Profit
    -$34.95 M (USD)
    -5.36
    as on Dec 31, 2024
  • EBITDA
    -$23.46 M (USD)
    -13.22
    as on Dec 31, 2024
  • Latest Funding Round
    $851.6 K (USD), Post-IPO

    Dec 23, 2015

  • Investors
  • Employee Count
    80

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of CrystalGenomics

CrystalGenomics is a publicly listed company on the KRX with ticker symbol 083790 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 083790 · Sector: Health technology · South Korea

Funding Insights of CrystalGenomics

Investors in CrystalGenomics

CrystalGenomics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Ministry of Health and Welfare and Korea-Seoul Life Science Fund.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
Government entity responsible for health and welfare services in Taiwan.
Locked Locked Locked
Premium access

Investor details for CrystalGenomics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CrystalGenomics

Investments
Premium access

Investment portfolio details for CrystalGenomics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - CrystalGenomics

Premium access

Detailed financials for CrystalGenomics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Crystalgenomics Comparisons

CrystalGenomics Primary company
Description
Clinical stage pharmacy company focused on the novel drugs i...
Location
Seongnam-si, South Korea
Founded Year
2000
Annual Revenue
$4.92 M (USD)
Net Profit
-$34.95 M (USD)
EBITDA
-$23.46 M (USD)
Employees
80
As of 2024
Premium access

Peer comparison for CrystalGenomics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of CrystalGenomics

Premium access

Detailed competitors of CrystalGenomics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Crystalgenomics

Premium access

Complete news archive for CrystalGenomics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CrystalGenomics

CrystalGenomics was founded in 2000 and raised its 1st funding round 12 years after it was founded.

CrystalGenomics is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

As of Dec 31, 2024, the latest employee count at CrystalGenomics is 80.

Annual revenue of CrystalGenomics is $4.92M as on Dec 31, 2024.

Crystal Genomics is a clinical stage biopharmaceutical company working on the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases.The Companys lead therapeutic program is Accelex, a next-generation NSAID for osteoarthritis is in NDA approval phase. Other products include CG400549 the antibiotic for MRSA and CG200745, a molecular targeted cancer therapeutic for solid tumors are in phase 2 development. Another molecular targeted cancer therapeutic CG026806 is in pre-clinical trials. It acquired Hwail Pharmaceutical on August 14, 2013 and has partnered with Daewoong Pharmaceutical for Acelex Commercialization in Korea. It also offers platform technology for drug discovery.

Yes, CrystalGenomics is publicly traded on KRX under the ticker symbol 083790.

CrystalGenomics has 2 investors. Key investors include Ministry of Health and Welfare, and Korea-Seoul Life Science Fund.

The ticker symbol of CrystalGenomics is 083790 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available